# Medtronic

the FDA approved Medtronic's Evolut FX+ TAVR for an expanded Redo-TAVR indication in August 2025, and Medtronic earned the CE Mark for redo-TAVI procedures, extending valve-in-valve therapy for high-risk patients.

Source: https://en.bioecon.ru/companies/medtronic/
Updated: 2026-06-28

- Country: Ireland
- Ticker: NYSE:MDT

## Technologies

- [Biomedical engineering & implants](https://en.bioecon.ru/technology/biomedical-engineering-implants/)
- [Implantable biosensors for chronic disease](https://en.bioecon.ru/technology/implantable-biosensors-chronic-disease/)
- [Ingestible biosensors / smart pills](https://en.bioecon.ru/technology/ingestible-biosensors-smart-pills/)